Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. grew its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 715.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 242,409 shares of the company's stock after acquiring an additional 212,664 shares during the period. Victory Capital Management Inc. owned about 0.46% of Janux Therapeutics worth $12,979,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Plato Investment Management Ltd raised its stake in shares of Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after acquiring an additional 187 shares during the period. Rhumbline Advisers increased its stake in Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after buying an additional 599 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after buying an additional 1,095 shares during the period. Virtu Financial LLC increased its stake in Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock worth $339,000 after buying an additional 2,419 shares during the period. Finally, Avanza Fonder AB purchased a new stake in Janux Therapeutics during the 4th quarter worth $139,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Remove Ads

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX traded down $0.67 during midday trading on Friday, hitting $30.68. The company's stock had a trading volume of 699,062 shares, compared to its average volume of 822,277. Janux Therapeutics, Inc. has a 1-year low of $28.92 and a 1-year high of $71.71. The firm's fifty day moving average price is $39.00 and its 200-day moving average price is $46.97. The firm has a market cap of $1.81 billion, a P/E ratio of -26.22 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. BTIG Research lifted their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Leerink Partners lifted their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 3rd. Finally, Stifel Nicolaus boosted their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $92.44.

Insider Activity

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the business's stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares of the company's stock, valued at $12,196,264.26. The trade was a 10.33 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 50,002 shares of company stock valued at $2,684,703. Company insiders own 29.40% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.